A Look At Royalty Pharma (RPRX) Valuation After Robust 2025 Results And Expansion Plans In Asia

Royalty Pharma (RPRX) has been in focus after reporting 2025 financial results that included 16% growth in total portfolio receipts, an 18% jump in Q4, and $4.7b in transactions.

See our latest analysis for Royalty Pharma.

The recent 13.9% 1 month share price return, building on a 19.9% 3 month gain and 22.2% year to date rise to US$47.48, suggests momentum has picked up as investors react to the 2025 results, the upcoming TD Cowen conference appearance and the planned expansion of the royalty business in Asia. The 1 year total shareholder return of 45.9% shows how dividends have added to price gains.

If Royalty Pharma’s move has you looking at where capital is flowing in healthcare, it could be a good moment to scan our screener of 31 healthcare AI stocks as potential next ideas.

With the shares up sharply and Royalty Pharma trading only about 9% below the average analyst target, the real question now is whether you are still getting a bargain or if the market is already pricing in future growth.

Most Popular Narrative: 6.9% Undervalued

Royalty Pharma’s most followed narrative points to a fair value of $51.00 per share versus the last close at $47.48. This frames the recent price strength in a valuation gap that is not fully closed yet.

Strategic reinvestment of large, stable cash flows into new and increasingly innovative royalty acquisitions, enhanced by improved data-driven diligence and risk management, allows Royalty Pharma to continually expand its portfolio with attractive economics, increasing operating leverage and net margins over time.

Read the complete narrative.

Want to see what is behind that confidence in cash flows and margins? This narrative leans on specific revenue growth, profitability and valuation assumptions that you will want to benchmark against your own view.

Result: Fair Value of $51.00 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, you still need to weigh up legal uncertainty around the Vertex Alyftrek royalty dispute, as well as competition for royalty deals that could pressure returns.

Find out about the key risks to this Royalty Pharma narrative.

Another View: Earnings Multiple Sends A Different Signal

While the narrative points to a fair value of $51.00 and labels Royalty Pharma as undervalued, the P/E tells a more cautious story. At 26.4x earnings, the shares sit above both the US Pharmaceuticals average of 20x and peers at 20.4x, and even above the 21.7x fair ratio. That richer multiple suggests less room for error if growth or deal quality does not match expectations. How comfortable are you paying a premium for this story?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of optimism and concern around Royalty Pharma feels finely balanced, take a closer look now and shape your own view using 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Royalty Pharma is already on your radar, do not stop there, broaden your watchlist now so you are not late to the next opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com